ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc (RCKT)

8.79
-0.66
(-6.98%)
Closed March 03 3:00PM
8.65
-0.14
( -1.59% )
Pre Market: 4:02AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
8.65
Bid
8.51
Ask
11.25
Volume
206
0.00 Day's Range 0.00
8.65 52 Week Range 30.94
Market Cap
Previous Close
8.79
Open
-
Last Trade
12
@
8.87
Last Trade Time
05:38:46
Financial Volume
-
VWAP
-
Average Volume (3m)
1,575,134
Shares Outstanding
106,629,701
Dividend Yield
-
PE Ratio
-0.03
Earnings Per Share (EPS)
-2.3
Revenue
-
Net Profit
-245.6M

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesio... Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Rocket Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RCKT. The last closing price for Rocket Pharmaceuticals was US$8.79. Over the last year, Rocket Pharmaceuticals shares have traded in a share price range of US$ 8.65 to US$ 30.94.

Rocket Pharmaceuticals currently has 106,629,701 shares outstanding. The market capitalization of Rocket Pharmaceuticals is US$937.28 million. Rocket Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.03.

RCKT Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.43-14.186507936510.0811.198.6515161799.29924371CS
4-1.88-17.853751187110.5311.458.65124185310.04343961CS
12-5.19-37.513.84158.65157513411.14406239CS
26-9.16-51.431779898917.8122.018.65120707813.57709273CS
52-22.23-71.988341968930.8830.948.6596582017.14992367CS
156-6.79-43.976683937815.4432.5257.56590412418.37870385CS
260-10.76-55.435342606919.4167.487.56571423322.10761714CS

RCKT - Frequently Asked Questions (FAQ)

What is the current Rocket Pharmaceuticals share price?
The current share price of Rocket Pharmaceuticals is US$ 8.65
How many Rocket Pharmaceuticals shares are in issue?
Rocket Pharmaceuticals has 106,629,701 shares in issue
What is the market cap of Rocket Pharmaceuticals?
The market capitalisation of Rocket Pharmaceuticals is USD 937.28M
What is the 1 year trading range for Rocket Pharmaceuticals share price?
Rocket Pharmaceuticals has traded in the range of US$ 8.65 to US$ 30.94 during the past year
What is the PE ratio of Rocket Pharmaceuticals?
The price to earnings ratio of Rocket Pharmaceuticals is -0.03
What is the reporting currency for Rocket Pharmaceuticals?
Rocket Pharmaceuticals reports financial results in USD
What is the latest annual profit for Rocket Pharmaceuticals?
The latest annual profit of Rocket Pharmaceuticals is USD -245.6M
What is the registered address of Rocket Pharmaceuticals?
The registered address for Rocket Pharmaceuticals is 300 DELAWARE AVENUE, SUITE 270, WILMINGTON, DELAWARE, 19801
What is the Rocket Pharmaceuticals website address?
The website address for Rocket Pharmaceuticals is www.rocketpharma.com
Which industry sector does Rocket Pharmaceuticals operate in?
Rocket Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PTIXProtagenic Therapeutics Inc
US$ 0.4223
(52.84%)
22.36M
WWWW International Inc
US$ 0.6298
(35.15%)
123.24k
LNKSLinkers Industries Ltd
US$ 0.85
(30.77%)
53
UOKAMDJM Ltd
US$ 0.194
(29.33%)
562.54k
GCLGCL Global Holdings Ltd
US$ 2.59
(28.22%)
522
SPGCSacks Parente Golf Inc
US$ 0.1067
(-43.84%)
10.69M
SYRESpyre Therapeutics Inc
US$ 11.00
(-38.68%)
4
EVCMEverCommerce Inc
US$ 6.20
(-36.28%)
7
OPCHOption Care Health Inc
US$ 22.01
(-35.19%)
17
EOLSEvolus Inc
US$ 9.32
(-35.01%)
8
SUNESUNation Energy Inc
US$ 0.2169
(-9.63%)
46.87M
BTOGBit Origin Ltd
US$ 0.4006
(25.46%)
41.37M
AGMHAGM Group Holdings Inc
US$ 0.13
(-2.26%)
23.92M
PTIXProtagenic Therapeutics Inc
US$ 0.4229
(53.06%)
22.36M
SPGCSacks Parente Golf Inc
US$ 0.1067
(-43.84%)
10.69M

RCKT Discussion

View Posts
Monksdream Monksdream 1 week ago
RCKT 10Q due MONDAY 2/24
๐Ÿ‘๏ธ0
Monksdream Monksdream 1 year ago
RCKT new 52 week high
๐Ÿ‘๏ธ0
make it happen make it happen 1 year ago
How's it up 38% @ $21.00 PPS when diluting $175,000,000 million @ $16.00??
๐Ÿ‘๏ธ0
trkyhntr trkyhntr 4 years ago
I have been away at hunting camp for a few weeks, and when I got back I was pleasantly surprised. This puppy has doubled! Any thoughts as to how much more upside there is?
๐Ÿ‘๏ธ0
ClayTrader ClayTrader 4 years ago
* * $RCKT Video Chart 12-09-2020 * *

Link to Video - click here to watch the technical chart video

๐Ÿ‘๏ธ0
Glider549 Glider549 5 years ago
Check out Seeking Alpha, January 27, article.
Lots of insider buying and Fast Track status.
๐Ÿ‘๏ธ0
RUSTYJ RUSTYJ 6 years ago
How you figure a lot power , Gravity takes it down
๐Ÿ‘๏ธ0
investor86 investor86 7 years ago
This got a lot of power!!
๐Ÿ‘๏ธ0
trkyhntr trkyhntr 7 years ago
This is a new board for this stock. Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock